MA54608B1 - Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer - Google Patents
Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancerInfo
- Publication number
- MA54608B1 MA54608B1 MA54608A MA54608A MA54608B1 MA 54608 B1 MA54608 B1 MA 54608B1 MA 54608 A MA54608 A MA 54608A MA 54608 A MA54608 A MA 54608A MA 54608 B1 MA54608 B1 MA 54608B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- heterobicyclic
- aza
- treating cancer
- mat2a
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des composés selon la formule i et leurs sels, tautomères et/ou isotopologues pharmaceutiquement acceptables tels que décrits dans la description. Les composés sont des inhibiteurs de l'isoforme 2a de la méthionine adénosyltransférase (mat2a). L'invention concerne également des compositions pharmaceutiques et des procédés d'utilisation des composés pour traiter des cancers, y compris certains cancers dans lesquels le gène codant pour la méthylthioadénosine phosphorylase (mtap) est supprimé.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785519P | 2018-12-27 | 2018-12-27 | |
PCT/US2019/068652 WO2020139991A1 (fr) | 2018-12-27 | 2019-12-27 | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MA54608A MA54608A (fr) | 2022-04-06 |
MA54608B1 true MA54608B1 (fr) | 2023-02-28 |
Family
ID=69400625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA54608A MA54608B1 (fr) | 2018-12-27 | 2019-12-27 | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer |
Country Status (36)
Country | Link |
---|---|
US (1) | US20220144820A1 (fr) |
EP (1) | EP3902803B1 (fr) |
JP (2) | JP7418441B2 (fr) |
KR (1) | KR20220051301A (fr) |
CN (1) | CN113454085B (fr) |
AR (1) | AR117544A1 (fr) |
AU (1) | AU2019416349B2 (fr) |
BR (1) | BR112021012595A2 (fr) |
CA (1) | CA3124952A1 (fr) |
CL (1) | CL2021001721A1 (fr) |
CO (1) | CO2021009879A2 (fr) |
CR (1) | CR20210410A (fr) |
DK (1) | DK3902803T3 (fr) |
EA (1) | EA202191801A1 (fr) |
ES (1) | ES2942310T3 (fr) |
FI (1) | FI3902803T3 (fr) |
GE (1) | GEP20237519B (fr) |
HR (1) | HRP20230161T1 (fr) |
HU (1) | HUE061834T2 (fr) |
IL (1) | IL284326B1 (fr) |
JO (1) | JOP20210172A1 (fr) |
LT (1) | LT3902803T (fr) |
MA (1) | MA54608B1 (fr) |
MD (1) | MD3902803T2 (fr) |
MX (1) | MX2021007829A (fr) |
PE (1) | PE20212090A1 (fr) |
PL (1) | PL3902803T3 (fr) |
PT (1) | PT3902803T (fr) |
RS (1) | RS64135B1 (fr) |
SA (1) | SA521422405B1 (fr) |
SG (1) | SG11202106637SA (fr) |
SI (1) | SI3902803T1 (fr) |
TW (1) | TWI816962B (fr) |
UA (1) | UA127525C2 (fr) |
WO (1) | WO2020139991A1 (fr) |
ZA (1) | ZA202104423B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
MX2021006841A (es) | 2018-12-10 | 2021-07-02 | Ideaya Biosciences Inc | Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?. |
CN116568677A (zh) | 2020-07-31 | 2023-08-08 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
CN115960098A (zh) * | 2020-09-11 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
WO2022206730A1 (fr) * | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | Composé de pyrimidopyrazine et son utilisation |
CN117412967A (zh) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
AU2022373595A1 (en) | 2021-10-20 | 2024-05-02 | Insilico Medicine Ip Limited | Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof |
US20230192679A1 (en) * | 2021-12-17 | 2023-06-22 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
CA3241698A1 (fr) * | 2021-12-21 | 2023-06-29 | Changyou MA | Inhibiteur heterocyclique de la methionine adenosyltransferase 2a |
WO2023169554A1 (fr) * | 2022-03-11 | 2023-09-14 | 赛诺哈勃药业(成都)有限公司 | Inhibiteur de méthionine adénosine transférase, son procédé de préparation et son utilisation |
WO2024080788A1 (fr) | 2022-10-13 | 2024-04-18 | 한미약품 주식회사 | Nouveau composé dérivé tricyclique et ses utilisations |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
AU2001290914A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP3507290A1 (fr) * | 2016-08-31 | 2019-07-10 | Agios Pharmaceuticals, Inc. | Inhibiteurs de processus métaboliques cellulaires |
DK3630724T3 (da) | 2017-05-22 | 2021-07-26 | Janssen Pharmaceuticals Inc | Substituerede indolinderivater som inhibitorer af virusreplikation af denguevirus |
MA52232A (fr) * | 2018-03-30 | 2021-02-17 | Agios Pharmaceuticals Inc | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer |
KR20220050832A (ko) * | 2018-12-27 | 2022-04-25 | 르 라보레또레 쎄르비에르 | Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법 |
CA3142340A1 (fr) * | 2019-05-31 | 2020-12-03 | Les Laboratoires Servier | Inhibiteurs heterobicycliques de mat2a et procedes d'utilisation pour le traitement du cancer |
-
2019
- 2019-12-27 US US17/418,442 patent/US20220144820A1/en active Pending
- 2019-12-27 EA EA202191801A patent/EA202191801A1/ru unknown
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/fr active Active
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/pl unknown
- 2019-12-27 PT PT198457962T patent/PT3902803T/pt unknown
- 2019-12-27 CN CN201980092742.2A patent/CN113454085B/zh active Active
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/ja active Active
- 2019-12-27 BR BR112021012595-7A patent/BR112021012595A2/pt unknown
- 2019-12-27 IL IL284326A patent/IL284326B1/en unknown
- 2019-12-27 TW TW108148216A patent/TWI816962B/zh active
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/hr unknown
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/fr active Application Filing
- 2019-12-27 MA MA54608A patent/MA54608B1/fr unknown
- 2019-12-27 RS RS20230240A patent/RS64135B1/sr unknown
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/es unknown
- 2019-12-27 SI SI201930515T patent/SI3902803T1/sl unknown
- 2019-12-27 CR CR20210410A patent/CR20210410A/es unknown
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/fi active
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/ro unknown
- 2019-12-27 CA CA3124952A patent/CA3124952A1/fr active Pending
- 2019-12-27 KR KR1020217023828A patent/KR20220051301A/ko unknown
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/da active
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/es unknown
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/hu unknown
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/lt unknown
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
- 2019-12-27 ES ES19845796T patent/ES2942310T3/es active Active
- 2019-12-27 AR ARP190103903A patent/AR117544A1/es unknown
- 2019-12-27 UA UAA202104321A patent/UA127525C2/uk unknown
- 2019-12-27 JO JOP/2021/0172A patent/JOP20210172A1/ar unknown
-
2021
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/es unknown
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-06-27 SA SA521422405A patent/SA521422405B1/ar unknown
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/es unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54608B1 (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
CR20210670A (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer | |
MX2021007833A (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer. | |
EA202092320A1 (ru) | Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли | |
PH12021551274A1 (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors | |
MA45920B1 (fr) | Inhibiteurs de pyridopyrimidinone cdk2/4/6 | |
PH12021550995A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
MA47079B1 (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
MA29713B1 (fr) | Derives de tetrahydroindolone et de tetrahydroindazolone | |
MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA31754B1 (fr) | Cis-imidazolines chirales | |
CR20220675A (es) | Análogos de nucleósido de 1´- ciano y usos de los mismos | |
TNSN07022A1 (fr) | Derives de pyridine | |
MA29926B1 (fr) | Derives de pyrazine | |
TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
MA27093A1 (fr) | Derives de sulfonamides, leur preparation et leur application comme medicaments. | |
MA27703A1 (fr) | Derives de diazepino-indole servant d'inhibiteurs de kinases | |
MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
MA28429B1 (fr) | Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases | |
TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
EA202190749A1 (ru) | Способы комбинированной терапии | |
MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
MX2021009206A (es) | Terapias contra el cancer. | |
MX2023003516A (es) | Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7). |